Polycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each of which has its own treatment approach and prognosis. Although current pharmacologic treatment is considered adequate for a relatively large group of PV patients, certain population segments are associated with substantial unmet need. As such, there is commercial opportunity for therapies able to differentiate from the current standard of care. Understanding the treatment dynamics is critical to identifying those opportunities.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: BMS, Incyte, Roche
Key drugs: Hydroxyurea, peg-interferon-alpha, ruxolitinib
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.